MET and neoplasm: MET signalling acts by phosphorylating various kinases, such as MAPK or PI3K/AKT, thereby modulating the expression of target genes like SLUG, MMP2 and BMP2 involved in motility, invasion, the cell cycle survival and tumour progression [29, 30, 31, 32, 33].